Fundraising FoxRev1 Ventures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
BiotechDigital HealthMedical DevicesColumbus, US
Robert Shalwitz(Executive Officer, Director)inRachael Wingo(Executive Officer)in
BoardTim Willis(Director)Faith Voinovich(Director)inBethany George(Director)in
Board seatWayne Embree· per SEC Form D
Co-investorsCincyTechJobsOhio VenturesJumpstart VenturesOhio Innovation Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.